At a glance
ClinicalIndex Comparison Record- ✓Histologically documented or cytologically confirmed Hodgkin lymphoma with CD30 expression
- ✓Relapsed or refractory after 1 line of prior therapy
- ✓Measurable disease >1.5 cm on CT or CT/PET imaging
- ✓ECOG performance status 0-2
- ✕Weight ≤40 kg
- ✕Uncontrolled illness or active infection
- ✕Known HIV, HCV, or HBV infection (except HIV with undetectable viral load and CD4 ≥200 on HAART)
- ✕Active CNS disease or history of brain metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Brentuximab Vedotin and Ibrutinib for Recurrent Hodgkin Lymphoma and Refractory Hodgkin Lymphoma. Completed, enrolled 39 participants across 3 sites.
Detailed Summary
This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as brentuximab vedotin, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma.
Study Details
Timeline
Interventions
Given IV
Given PO